Atea presents initial Phase 2 data for bemnifosbuvir, ruzasvir combination

Atea Pharmaceuticals announced new data from the lead-in cohort of the Company’s ongoing Phase 2 combination study of bemnifosbuvir, an oral nucleotide NS5B polymerase inhibitor, and ruzasvir, an oral NS5A inhibitor, for the treatment of hepatitis C virus. With an 8-week treatment duration, the Phase 2 data from the lead-in cohort of non-cirrhotic patients showed a 97% sustained virologic response rate at 12 weeks post-treatment, which is the primary efficacy endpoint of the study. The Company will also present preclinical data further demonstrating a high barrier to resistance and pharmacokinetics for bemnifosbuvir and a low risk of drug-drug interactions for ruzasvir. Results from the lead-in cohort of the Phase 2 study also showed a 100% SVR12 rate in participants infected with genotype 3, a historically difficult-to-treat genotype of HCV. The combination regimen was well tolerated, with no drug-related severe adverse events or treatment discontinuations. Based on these positive data from the lead-in cohort, the Phase 2 study continues, with the aim of enrolling up to an additional 220 subjects, including those with compensated cirrhosis